EFAI Business Summary

Ever Fortune.AI Co., Ltd. (6841.TWO) is a leading Taiwan-based medical artificial intelligence developer specializing in the commercialization of deep learning algorithms for clinical diagnostics and hospital workflow optimization. The company generates revenue primarily through a B2B model involving the licensing of its proprietary AI software suites, provision of medical big data analytics, and the deployment of its cloud-based biomedical platforms. Its business is structured into three core segments: Medical AI (focusing on neurology, cardiology, and oncology), Cloud Medical Platforms for remote diagnostics, and Medical Big Data services. Ever Fortune.AI distinguishes itself as the first medical AI company in Taiwan to go public, having secured over 40 global regulatory clearances, including 12 U.S. FDA approvals. It competes directly with domestic players such as Medimaging Integrated Solution (MiiS) and AHEAD Medicine, as well as international firms like Renalytix and Lifespin, positioning itself as a high-barrier-to-entry specialist in complex organ-at-risk (OAR) segmentation and cardiovascular risk assessment. The company was founded in 2018 as a strategic spin-off from the China Medical University Hospital (CMUH) by Dr. Chang-Hai Tsai, who serves as the founding Chairman and is a prominent figure in Taiwan’s healthcare sector. The leadership team is currently headed by Chairman and General Manager Dr. Ming-Fong Chen, a distinguished cardiologist and former Superintendent of National Taiwan University Hospital, and General Manager Dr. Yu-Cheng Lee, an industrial engineering expert and former Dean of the School of Management at Chung Hua University. Technical leadership is spearheaded by Dr. Ti-Hao Wang, Director of Research & Development, who brings extensive experience in radiation oncology and medical intelligence. Ever Fortune.AI is backed by a robust board and shareholder base that includes major strategic investors such as Quanta Computer, Trend Micro, and Center Laboratories, reflecting a strong convergence of medical expertise and information technology pedigree.